Pancreas exocrin. Pancreas endocrin. Pancreatite acute Pancreatite cronice Afectiuni ereditare ale pancreasului Tumori pancreatice

Similar documents
Appendix 4: WHO Classification of Tumours of the pancreas 17

Pancreatic intraepithelial

Pancreatic Cytopathology: The Solid Neoplasms

Genetics of Pancreatic Cancer. October 6, If you experience technical difficulty during the presentation:

Pancreas (Exocrine) Protocol applies to all carcinomas of the exocrine pancreas.

Neoplasias Quisticas del Páncreas

Select problems in cystic pancreatic lesions

Pancreatic Cysts. Darius C. Desai, MD FACS St. Luke s University Health Network

p53 expression in invasive pancreatic adenocarcinoma and precursor lesions

Pancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)

Surveillance of Individuals At High Risk For Developing Pancreatic Cancer

Pancreatic Cancer: The ABCs of the AJCC and WHO

PANCREAS DUCTAL ADENOCARCINOMA PDAC

An Approach to Pancreatic Cysts. Introduction

Evaluation and Management of Cystic Lesions of the Pancreas: When to Resect, When to Follow and When to Forget

incidence rate x 100,000/year

Epidemiology and genetics of pancreatic cancer

Pancreatic Cystic Lesions 원자력병원

Intraductal Papillary Mucinous Neoplasms: We Still Have a Way to Go! Francesco M. Serafini, MD, FACS

40th European Congress of Cytology Liverpool, UK, 2-5 th October 2016

Anatomy of the biliary tract

H&E, IHC anti- Cytokeratin

Combatting Pancreatic Cancer: Keys to Early Recognition and Diagnosis

The Pancreas. Basic Anatomy. Endocrine pancreas. Exocrine pancreas. Pancreas vasculature. Islets of Langerhans. Acinar cells Ductal System

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

Hepatobiliary and Pancreatic Malignancies

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

The international health care burden of cancers of the gastrointestinal tract and liver

Pancreas Cancer Genomics

Pancreatobiliary Frozen Section Nightmares

Standardized Terminology in Pancreatobiliary Cytology: The Papanicolaou Society Guidelines

CYTOLOGY OF EUS- GUIDED FNA OF THE PANCREAS AND THE UPPER GI TRACT

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14

Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

7th Annual Symposium on Gastrointestinal Cancers " St. Louis, Mo, 9/20/08

Overview of 2010 Hong Kong Cancer Statistics

Dr Claire Smith, Consultant Radiologist St James University Hospital Leeds

Kenneth D. Chi, MD Medical Director GI Lab Advocate Lutheran General Hospital

The pathology of pancreas

Collecting Cancer Data: Pancreas

Neuro-endocrine and pancreatic non-adenocarcinomas. Marc Engelbrecht, AMC, Amsterdam

GASTROINTESTINAL IMAGING STUDY GUIDE

Radiology Pathology Conference

Morphologic features in cystic lesions of pancreas-a retrospective analysis

Matthew McCollough, M.D. April 9, 2009 University of Louisville

An investigation of pancreatic volume by disease using pancreatic volumetry

Cancer in Estonia 2014

Poblacions amb alt risc de càncer de pàncrees. Quin seguiment hem de fer?

Pancreatic Cancer. BIOLOGY: Not well defined (genetic and enviromental factors) CLINICAL PRESENTATION: Abd pain, jaundice, weight loss.

3 cell types in the normal ovary

Management A Guideline Based Approach to the Incidental Pancreatic Cysts. Common Cystic Pancreatic Neoplasms.

Overview of 2009 Hong Kong Cancer Statistics

Causes of pancreatic insufficiency. Eugen Dumitru

Recommendations for the Reporting of Pancreatic Specimens Containing Malignant Tumors

Citation American Journal of Surgery, 196(5)

The Future of Cancer. Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong. Session Number: WBR8

5/21/2018. An Update on Pancreas Neoplasms. Arief Suriawinata, M.D. Lines of Differentiation in Pancreatic Neoplasms

Adenocarcinoma of the pancreas

Colorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.

Predictive factors for invasive intraductal papillary mucinous neoplasm of the pancreas

Case Scenario 1. Discharge Summary

Small Intestine. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition

Pancreas composed of 2 parts: 1- exocrine gland 2- endocrine gland

CODING TUMOUR MORPHOLOGY. Otto Visser

Disclosure of Relevant Financial Relationships

Outline. Intraductal Papillary Mucinous Neoplasm (IPMN) Guideline Review 4/6/2017. Case Example Background Classification Histology Guidelines

General Surgery PURPLE SERVICE MUHC-RVH Site

Evaluation of AGA and Fukuoka Guidelines for EUS and surgical resection of incidental pancreatic cysts

Evaluation of hereditary syndromes that include pancreatic cancer

Gastroenterology Tutorial

Team approach is essential incorporating: radiology, gastroenterology, surgery and pathology Successful performance is operator dependent

Genetic testing and pancreatic disease

ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts

Patient History. A 58 year old man presents with a 16 mm cyst in the pancreatic tail. The cyst is unilocular with a thick wall and no mural nodule.

Colorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY

2014 International Journal of Medical Science Research and Practice available on

Navigators Lead the Way

Cancer A Superficial Introduction

Endoscopic Ultrasonography Clinical Impact. Giancarlo Caletti. Gastroenterologia Università di Bologna. Caletti

X-ray Corner. Imaging of The Pancreas. Pantongrag-Brown L

Outcomes Report: Accountability Measures and Quality Improvements

Metastatic pancreatic cancer, icd-10

The Role of Molecular Analysis in the Diagnosis and Surveillance of Pancreatic Cystic Neoplasms

Colonic Polyp. Najmeh Aletaha. MD

BREAST CANCER d an BREAST SELF EXAM

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval

Biliary cytolgy and pancreatic endoscopic ultrasound-guided FNA. Leena Krogerus Helsinki, FINLAND

Pancreatic Cystic Neoplasms: Guidelines and beyond

CT 101 :Pancreas and Spleen

Sarah Burton. Lead Gynae Oncology Nurse Specialist Cancer Care Cymru

Gastric Cancer Histopathology Reporting Proforma

Chronic pancreatitis mimicking intraductal papillary mucinous neoplasm of the pancreas; Report of tow cases

ICD-O Morphology code. R=Rare Tier Tumour ICD-O Topography code C30.0, C31

*

Carcinoembryonic Antigen

Stage 4 gastric adenocarcinoma icd 10

DOWNLOAD PDF TUMORS OF THE PANCREAS

2018 Texas Cancer Registry Annual Report

NEOPLASIA. 3. Which of the following tumour is benign a. Chondrosarcoma b. Osteochondroma c. Chondroblastoma d. Ewing s tumour e.

Transcription:

Pancreas exocrin Pancreatite acute Pancreatite cronice Afectiuni ereditare ale pancreasului Tumori pancreatice Pancreas endocrin Diabetul zaharat Tumorile neuroendocrine PET-NET

Pancreas exocrin Pancreatite acute Pancreatite cronice Afectiuni ereditare ale pancreasului Tumori pancreatice Pancreas endocrin Diabetul zaharat Tumorile neuroendocrine PET-NET

Pancreatita acuta urgenta garda UPU Pancreatita cronica durere abdominala trenanta Medic de familie! Chirurg sau Internist Tumori pancreatice Eventual internist din policlinica Nutritionist, medic de familie, endocrinolog, psihiatru, gastroenterolog 4

Necesita explorari Uneori sofisticate Necesara internare De obicei gastroenterolog 5

Incidenta 4,9-35 %ooo /an In crestere in tarile europene Cauza majora de spitalizare in SUA Cauza = crester consum de alcool Mortalitate 5-17% Vege SS et al Gastrointestinal epidmiology 2007

Incidence of AP increased between 2000 and 2005 from 13.2 to 14.7 Incidence of AP for males increased from 13.8 to 15.2, for females from 12.7 to 14.2 Mortality for AP fluctuated between 6.9 and 11.7 per million persons/ year and was almost similar for males and females. Incidence and mortality of AP and CP increased markedly with age. CONCLUSION: Incidence of AP steadily increased. Mortality for AP remained fairly stable. Patient burden and health care costs probably will increase because of an ageing BW Ml Spanier et alworld J Gastroenterol 2013 May 28; 19(20): 3018-3026

European studies increase in the incidence rate of acute pancreatitis 922 patients with confirmed diagnosis of AP ( (2000 2009)in 1 hospital incidence rate varied from 24 to 35/100 000 inhabitants annually. Mean age was 60 ± 16 years. 53% men and 47% women etiologies of AP were biliary stones in 60% and alcohol abuse in 19% of patients. severe in 50% and 43 Davor Stimac et al - Gastroenterology Research and Practice Volume 2013, Article ID 956149,

Cauza Pancreatita cronica Fibroza chistica Chirurgia pancreatica Prevalenta 3,9/100.000 EU 3,3/100.000 Franta 4,2 /100000 Germania 2,9/100000 Italia 3.0/100000 Spania 5,5/100000 UK Mattson,Jakc Report 2005- Pancreatic exocrine insuffiency epidemiology

Loss of functioning parenchyma Chronic pancreatitis Cystic Fibrosis Tumours Resections secretion despite intact parenchyma Obstruction endogenous stimulation (coeliac, Crohns, DM) Asynchrony Gastric resections Short bowel syndrome Crohns, DM Enzyme inactivation Zollinger-Ellison syndrome

Prevalenta Creste cu varsta Mai mare la barbati Distributia pe sex si varsta difera f de etiologie Alcoolica mai frecv la Barbati Idiopatica si hiperlipemica la femei Fiborza chistica egala femei barbati Fibroza chistica mai frecv in primul an de viata Pancreatita cronica si chirurgie la varstnic Rothenbacher D, etal Scand J Gast 2005;40(6)

Insuficienta pancreatica exocrina Pancreatita cronica Pancreatita senila Pancreatita acuta Cauze Rezectie gastrica Fibroza chistica Pancreatectomie Indicatie PEI Plenitudine Meteorism Steatoree Dispepsie Semne simptome Greata / varsaturi Pierderea apetitului Malabsortie Intoleranta alimentelor Pierdere in greutate Durere abdominala

Pancreatita cronica PA Forma usoara Forma severa Pseudochist Recidiva Restitutio ad integrum PA Pancreatita acuta PC Incidenta PC este de 3,5-4 / 100 000 locuitori. Prevalenta/Predominanta de vârsta si sex: pancreatita cronica afecteaza preponderent barbatii în vârsta de 35-45 ani (de 3 ori mai frecventa decât la femei). PC Pancreatita cronica Klöppel & Maillet, Hepatogastroenterol 38:408, 1991

INCIDENTA = 3-10 %ooo loc PREVALENTA = 5.5-30 %ooo loc!!este in crestere Variaza geografic Tara Incidenta /100 000 loc Sursa Japonia 5.7 JGastroenterol 38(4):315-26, 2003 Elvetia 1.6 Eur J Gastroenterol Hepatol.13(6):749-50, 2001 Finlanda 23 Pancreatology.2(5): 469-77, 2002 Cehia 7.9 idem 14

Inciența este de 6-7 /100.000 locuitori în vest 80% sex masculin. Vârsta medie depinde de etiologie, ~ 40-45 ani la PC alcoolică, ~ 25-30 la PC idiopatică, ~ 15-20 la cei PC ereditară, ~ 10 ani la copii cu PC tropicală. Incidența este crescută la negri față de albi. James Jupp a,1, David Fine b,2, ColinD.Johnson c,*best Practice&ResearchClinicalGastroenterology24(2010)219e231

Etiologie. Consumul excesiv de alcool 70-85% Fumatul, l factor de risc extern cancerului pancreatic. Alte cauze rare de PC: hipercalcemia peste 12mg/dl (3mmol/l (1% din PC sunt datorate hiperpth, 7% din hiperpth au și PC). PC tropicală. PC genetică. PC autoimună PC obstructivă. PC idiopatică. 10% din cazurile de PC James Jupp a,1, David Fine b,2, ColinD.Johnson c,*best Practice&ResearchClinicalGastroenterology24(2010)219e231

Benigne Maligne Epiteliale Nonepiteliale Exocrine Endocrine

Epithelial tumours Benign Serous cystadenoma 8441/01 Mucinous cystadenoma 8470/0 Intraductal papillary-mucinous adenoma 8453/0 Mature teratoma 9080/0 Borderline (uncertain malignant potential) Mucinous cystic neoplasm with moderate dysplasia 8470/1 Intraductal papillary-mucinous neoplasm with moderate dysplasia Solid-pseudopapillary neoplasm 8452/1 Malignant Ductal adenocarcinoma 8500/3 Mucinous noncystic carcinoma 8480/3 Signet ring cell carcinoma 8490/3 Adenosquamous carcinoma 8560/3 Undifferentiated (anaplastic) carcinoma 8020/3 Undifferentiated carcinoma with osteoclast-like giant cells 8035/3 Mixed ductal-endocrine carcinoma 8154/3 Serous cystadenocarcinoma 8441/3 Mucinous cystadenocarcinoma 8470/3 non-invasive 8470/2 invasive 8470/3 Intraductal papillary-mucinous carcinoma 8453/3 non-invasive 8453/2 invasive (papillary-mucinous carcinoma) 8453/3 Acinar cell carcinoma 8550/3 Acinar cell cystadenocarcinoma 8551/3 Mixed acinar-endocrine carcinoma 8154/3 Pancreatoblastoma 8971/3 Solid-pseudopapillary carcinoma 8452/3 Others Non-epithelial tumours Secondary tumours

Primary Tumour (T) TX Primary tumour cannot be assessed T0 No evidence of primary tumour Tis Carcinoma in situ T1 Tumour limited to the pancreas, 2 cm or less in greatest dimension T2 Tumour limited to the pancreas, more than 2 cm in greatest dimension T3 Tumour extends directly into any of the following: duodenum, bile duct, peripancreatic tissues3 T4 Tumour extends directly into any of the following: stomach, spleen, colon, adjacent large vessels4 Regional Lymph Nodes (N) NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 Regional lymph node metastasis N1a Metastasis in a single regional lymph node N1b Metastasis in multiple regional lymph nodes Distant Metastasis (M) MX Distant metastasis cannot be assessed M0 No distant metastasis MI Distant metastasis Stage grouping Stage 0 Tis N0 M0 Stage I T1 N0 M0 T2 N0 M0 Stage II T3 N0 M0 Stage III T1 N1 M0 T2 N1 M0 T3 N1 M0 Stage IVA T4 Any N M0 Stage IVB Any T Any N M1

Malvezi M et al - Annals of Oncology 28 feb 2012 Sex Cancer Recorded deaths 2007 Predicted number of deaths 2012 Men Stomach 37424 33926 colon and rectum 85244 89117 Pancreas 35022 39088 Lung 183019 183592 Prostate 68282 69960 Leukemias 21553 22320 All cancers (malignant and benign) 706619 717398 Women Stomach 25060 21138 Colon and rectum 75294 73989 Pancreas 34965 38443 Lung 69115 78658 Breast 89012 88101 Uterus (cervix and corpus) 27393 26720 Leukemias 17884 18605 All cancers (malignant and benign)554515 565703

10th most frequent cancer the 8th leading cause of cancer-related death Incidence men: 7,3 8,7 per 100.000 women: 4,5 5,7 per 100.000 >95% of patients are dying of their disease No survival increases have been observed in the last years S. Cascinu et al. Annals of Oncology 21 (Supplement 5): v55 v58, 2010

Demographic factors Old age (most reliable and important predictor) Sex (more common in males than in females) Ethnic origin (mortality highest in black populations) Genetic factors and medical conditions Family history (one first degree 2,3 fold increased risk) Hereditary pancreatitis Hereditary non-polyposis colorectal cancer Ataxia-telangiectasia Peutz-Jeghers syndrome (132 fold increased risk) Familial breast cancer (BRCA2 mutations) Familial atypical multiple mole melanoma (germline mutations in p16) Chronic pancreatitis (2% per decade) Diabetic mellitus Gastrectomy Deficiency in carcinogen metabolism and DNA repair Environmental and lifestyle factors Cigarette smoking Occupational exposures Low dietary intake of fruits and vegetables Food preparation and cooking methods (grilling or charring confers the highest risk) James L Abbruzzese et al. Lancet 2004; 363: 1049 57

Enviromental factors cigarette smoking* RR = at least 1,5 especially in smokers with GSTT1 (homozygous deletions of gene glutathione S-transferase T1) risk level returns to baseline by 15 years after cessation dietary** excessive fat or meat diabetes mellitus*** diagnosed within the preceding two years associated with obesity *Ghadirian P. Cancer 1991; 67:2664-70 **Farrow DC. Am J Epidemiol 1990; 132:423-31 ***Gullo L. N Engl J Med 1994; 331:81-4

Normal pancreas has 3 types of epithelial cells Acinar cells 80% Ductal cells 10-15% Endocrine cells - <5% 95% of neoplasms arise from the exocrine elements - ductal and acinar cells Ductal adenocarcinoma = 85% to 90% of pancreatic tumors Localization: 60-70% head, 5-10% body,10-15% tail

Benign Serous cystadenoma Mucinous cystadenoma Intraductal papillary mucinous adenoma Mature cystic teratoma Borderline (uncertain malignant potential) Mucinous cystic tumor with moderate dysplasia Intraductal papillary mucinous tumor with moderate dysplasia Solid-pseudopapillary tumor Malignant Ductal adenocarcinoma Osteoclast-like giant cell tumor Serous cystadenocarcinoma Mucinous cystadenocarcinoma (noninvasive or invasive) Intraductal papillary mucinous carcinoma (noninvasive or invasive) Acinar cell carcinoma Pancreatoblastoma Solid-pseudopapillary carcinoma Miscellaneous carcinomas Hamilton SR, Aaltonen LA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC

successive accumulation of gene mutations 3 precursor lesions*: Primary histologic precursor of pancreatic cancer = pancreatic intraductal neoplasia (PanIN) PanIN 1a,b (minimally dysplastic epithelium) pancreatic ** activation of the KRAS2 oncogene, inactivation of the tumor-suppressor gene CDKN2A inactivation of the tumor-suppressor genes TP53 and deleted in cancer 4 (DPC4, also known as the SMAD4 PanIN 2,3 (severe dysplasia) Mucinous cystic neoplasm (MCN) intraductal pancreatic mucinous neoplasm (IPMN) * Jason Klapman. Cancer Control October 2008, Vol. 15, No. 4 ** Feldmann G. J Hepatobiliary Pancreat Surg 2007;14:224-32

Normal duct PanIN Ia PanIN Ib PanIN II PanIN III Cancer MCN low grade Normal duct Intermediate grade High grade IPMN low grade Jason Klapman. Cancer Control October 2008, Vol. 15, No. 4

Gene/ chromosomal region (oncogenes and tumor supression) K-ras (12p) >90% p16 CDKN2A (9p) >95% PK53 (17p) 50%-70% SMAD4/DPC4 (18q) 55% AKT2 (19q) 10%-20% MYB (6q) 10% AIB1 (20q) 10% BRCA2 (13q) 7%-10% LKB1/STK11 (19p) <5% MKK4 (17p) <5% TGF-β-R1 (9q) or TGF-β-R2 (3p) <5% RB1 (13q) <5% % of tumors with genetic mutation Modified from Hruban RH, Wilentz RE. The pancreas. In: Kumar V, Abbas AK, Fausto N, editors. Robbins and Cotran pathologic basis of disease. 7th ed. Philadelphia: Elsevier; 2005

Oncogenes K-ras present in 90% of cancers frequency of mutations = extent of dysplasia Can be detected in chronic pancreatitis without neoplasia Tumor suppressor genes TP53 mutations chromosomal instability cancer P16 mutation associated with FAMMM syndrome (melanoma and pancreatic cancer) associated with decreased survival DPC4 = effect on cell cycle regulation and cell differentiation Other: up-regulation of EGF, telomere shortening

Cancer Incidence Oesophagus 578 Stomach 2650 Colorectum 4554 Liver 1279 Gallbladder 293 Pancreas 1682 Lung 8387 Prostate 3620

Cancer Incidence Oesophagus 103 Stomach 1351 Colorectum 4142 Liver 692 Gallbladder 355 Pancreas 1184 Breast 7929 Cervix uteri 3402 Corpus uteri 1208 Ovary 1686

Male Female both Lung Breast Lung Colorectum Colorectum Colorectum Prostate Cervix uteri Breast Stomach Lung Stomach Bladder Ovary Prostate Romania GLOBOCAN 2008

Statisitica MS PCR in 2011 975 cazuri = 4,8 %ooo locuitori Studii Diculescu et al Romanian J gastroenterol 2005 studiu de cohorta PAC 62 pacienti sp Elias Hajjar N et al Chirurgia 2012 81 pacienti Chirurgie 3 Cluj Hecser L et al Rom J Legal Med2009 case reports PAC Diaconu B J Gastrointest Liver Disease 2009 SPINK 1 mutatie in 94 pac cu PCR

Cauze Raportarea in functie de ICM/DRG modifica formularea diagnostica Raportarea in teritoriu deficitara Patologie complexa ce implica multe esaloane medicale ( primara, secundara tertiare) fiecare cu raportari diferite

Dezavantaje Simptomatologia in patologia pancreatica apare de f multe ori f tardiv in stadii avansate Diagnosticul se bazeaza pe explorari imagistice sofisticate inabordabila pt metode de screening Avantaje Pancreatitele acute se interneaza doar in spitalele de urgenta Rata incidentei in tumorile maligne pancreatica este practic egala cu cea a mortalitatii Putine cazuri de Pancreatite cronice

Abord multidiscliplinar Standardizarea diagnosticelor APPR => registre pe domenii restranse de cazuri Pancreatite ereditare Tumori pancreatice rare Tumori neuroendocrine (PET-NET)

Incidenta pancreatitelor acute este in crestere in tarile occidentale ( si la noi?) Cunoasterea corecta a abordarii PAC poate salva vieti Pancreatitele cronice sunt subdiagnosticate si subestimate Tumorile pancreatice sunt in crestere si nu sunt metode de screening eficient actual